Oral N-Acetyl Cysteine Lowered IL 6 Level Among Stage V Chronic Kidney Disease Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)

Evi Nurhayatun


Background. IL 6  level is increased in stage V CKD patients on CAPD. N-Acetyl Cysteine is a compound containing thiol with antioxidant and anti-inflammatory effects.

Objective. To examine the effect of oral NAC on IL 6 level in stage V CKD patients on CAPD.

Method. An experimental research with Randomized Double Blind Control Trial,  involving 30 CKD patients on CAPD in Dr Moewardi Hospital. They were divided into control group/placebo (15 patients) and oral NAS treatment group (15 patients). IL 6 level was measured before and after 8 weeks of treatment.

Result. Level of IL 6  before and after treatment in control group were (8.13 + 7.62  vs 11.16 + 8.32 , p= 0,001), significantly (p<0,001). Level of IL 6 before and after treatment in treatment group were (9.72 + 7.29 vs 6.09 + 3.82, p = 0,002); lowered significantly (p<0,05).

Conclusion. Oral NAC lowered the level of IL 6 in stage V CKD patients on CAPD.


N-Acetyl Cysteine, CAPD, IL 6

Full Text: